Organon & Co. Investor Notice: Robbins LLP Reminds Investors of the Class Action Against OGN

Core Viewpoint - A class action has been filed against Organon & Co. for allegedly misleading investors regarding its debt reduction strategy and the prioritization of capital allocation through dividends [1][2]. Allegations - The complaint claims that during the class period, Organon misrepresented its capital allocation strategy, emphasizing dividends as a "1 capital allocation priority" while concealing the importance of its debt reduction strategy post-acquisition of Dermavant [2][3]. - It is alleged that this misrepresentation led to a significant reduction in the regular quarterly dividend by 70% [3]. Impact of Disclosure - The truth about the company's financial strategy was revealed on May 1, 2025, when Organon announced a drastic cut in its dividend payout from $0.28 to $0.02, aimed at recapturing capital [4]. - Following this announcement, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% [4].